Abstract
Zika virus has spread around the world with rapid pace in the last five years. Although symptoms are typically mild and unspecific, Zika’s major impact occurs during pregnancy, generating a congenital syndrome. Serology plays a key role in its diagnosis. However, its use is limited due to the uncertainty caused by the cross-reaction of antibodies elicited in response to other flavivirus infections when tested in direct immunoassays. Using a panel of previously generated anti-Zika non-structural protein 1 (NS1) nanobodies, a set was selected that only recognizes epitopes present in Zika and is immunogenic to humans. A proper arrangement of these nanobodies was made and conditions were optimized in order to develop a novel serology assay. This new ELISA relies on the inhibition of the binding of a set of selected nanobodies to Zika-immobilized NS1 when previously incubated with Zika convalescent sera. Using the developed blocking of binding assay, it was possible to discriminate between Zika-specific and cross-reactive antibodies in serum samples from infections with Zika and other flaviviruses.
Funder
Agencia Nacional de Investigación e Innovación
Comisión Sectorial de Investigación Científica
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology
Reference26 articles.
1. Zika virus (I). Isolations and serological specificity;Dick;Trans. R. Soc. Trop. Med. Hyg.,1952
2. Zika virus outbreak in Brazil;Heukelbach;J. Infect. Dev. Ctries.,2016
3. Zika virus in the Americas: Early epidemiological and genetic findings;Faria;Science,2016
4. Zika virus, French polynesia, South pacific, 2013;Roche;Emerg. Infect. Dis.,2014
5. Potential sexual transmission of Zika virus;Musso;Emerg. Infect. Dis.,2015
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献